Literature DB >> 18615150

Modelling anxiety in humans for drug development.

Martin Siepmann1, Peter Joraschky.   

Abstract

Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO(2) inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.

Entities:  

Keywords:  Anxiety; anoxiolytic; drug development; humans; model

Year:  2007        PMID: 18615150      PMCID: PMC2435339          DOI: 10.2174/157015907780077114

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


  109 in total

1.  Adenosine A1 receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice.

Authors:  Rui D S Prediger; Luciano C Batista; Reinaldo N Takahashi
Journal:  Eur J Pharmacol       Date:  2004-09-19       Impact factor: 4.432

2.  Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.

Authors:  J Bradwejn; D Koszycki; C Shriqui
Journal:  Arch Gen Psychiatry       Date:  1991-07

Review 3.  Avenues of investigation for the role of catecholamines in anxiety.

Authors:  I J Kopin
Journal:  Psychopathology       Date:  1984       Impact factor: 1.944

4.  The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men.

Authors:  M Siepmann; S Krause; P Joraschky; M Mück-Weymann; W Kirch
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

5.  Fear-potentiated startle in adolescent offspring of parents with anxiety disorders.

Authors:  C Grillon; L Dierker; K R Merikangas
Journal:  Biol Psychiatry       Date:  1998-11-15       Impact factor: 13.382

6.  Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients.

Authors:  D S Charney; S W Woods; J H Krystal; L M Nagy; G R Heninger
Journal:  Acta Psychiatr Scand       Date:  1992-10       Impact factor: 6.392

7.  Alcohol and fear-potentiated startle: the role of competing cognitive demands in the stress-reducing effects of intoxication.

Authors:  J J Curtin; A R Lang; C J Patrick; W G Stritzke
Journal:  J Abnorm Psychol       Date:  1998-11

8.  Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones.

Authors:  J Bradwejn; C de Montigny
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

9.  The effects of caffeine on plasma MHPG, subjective anxiety, autonomic symptoms and blood pressure in healthy humans.

Authors:  D S Charney; M P Galloway; G R Heninger
Journal:  Life Sci       Date:  1984-07-09       Impact factor: 5.037

10.  Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.

Authors:  A W Goddard; S W Woods; D E Sholomskas; W K Goodman; D S Charney; G R Heninger
Journal:  Psychiatry Res       Date:  1993-08       Impact factor: 3.222

View more
  1 in total

1.  Dynamic Tracking of State Anxiety via Multi-Modal Data and Machine Learning.

Authors:  Yue Ding; Jingjing Liu; Xiaochen Zhang; Zhi Yang
Journal:  Front Psychiatry       Date:  2022-03-02       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.